Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

trialsTrialRecruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

A phase 2 trial of Acalabrutinib, Rituximab in diffuse large b-cell lymphoma, run by AstraZeneca, now recruiting.

Also called: ACRUE

Overview Connected6

Overview

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL is a phase 2 interventional study registered as NCT05952024 by AstraZeneca, with 80 participants planned, started 2024-07-16 and due to reach its primary completion in 2029-04-22. Interventions recorded: Acalabrutinib, Rituximab. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

Setting

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

Phase

Phase 2

Sponsor

AstraZeneca

Registry

Started

2024-07-16

Enrolled

80 enrolled

Connected

Similar pages

Trial
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Trial
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Trial
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Trial
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Trial
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Trial
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Trial
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Trial
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.

cancers

Diffuse large B-cell lymphoma

technologies

Monoclonal antibodies Small-molecule kinase inhibitors

drugs

ApprovedSmall-molecule covalent BTK inhibitor (second generation)

Acalabrutinib · Calquence

ApprovedMonoclonal antibody (anti-CD20, chimeric)

Rituximab · Rituxan / MabThera (and biosimilars)

companies

Evidence strength30/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
80 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT05952024

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Diffuse large B-cell lymphoma

Technologies

Small-molecule kinase inhibitors
Monoclonal antibodies

Products

Acalabrutinib
Rituximab

Companies

AstraZeneca

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05952024/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05952024.

WebMCP tools registered on this page: onco_search, onco_get_entity.